Gastrointestinal Therapy Agents Use

    Basic Details
    Date Posted
    Thursday, September 12, 2013
    Status
    Complete
    Medical Product
    aprepitant
    cimetidine
    dexlansoprazole
    dicyclomine HCL
    fosaprepitant dimeglumine
    lubiprostone
    mesalamine
    nizatidine
    sucralfate
    Description

    Summary table assessment of the use of ten selected gastrointestinal (GI) therapies including Aprepitant, Fosaprepitant Dimeglumine, Cimetidine, Dexlansoprazole, Dicyclomine HCL, Lubiprostone, Mesalamine, Nizatidine, and Sucralfate. Results were generated using the Mini-Sentinel Distributed Query Tool and the Dispensing Summary Table.Summary tables are precompiled stratified counts. Queries were executed in July 2012. This report includes data from 16 Data Partners.

    If you are using a web page screen reader and are unable to access this document, please contact the Mini-Sentinel Operations Center for assistance by clicking on the Submit Comments link above or sending an email requesting assistance to info@mini-sentinel.org.

    The information contained on this website is provided as part of FDA's commitment to place knowledge acquired from the Mini-Sentinel pilot in the public domain as soon as possible. Please read the disclaimer.

    Additional Details
    FDA Center
    CDER
    Time Period
    2000 - 2011
    Study Type
    Summary Table
    Assessment Type
    Exploratory Analyses
    Population / Cohort
    All children 14 years of age and younger
    Data Sources
    Mini-Sentinel Distributed Database (MSDD)